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Borna disease virus (BDV) has a non-segmented, negative-stranded RNA genome and causes persistent
infection in many animal species. Previous study has shown that the activation of the IkB kinase (IKK)/
NF-kB pathway is reduced by BDV infection even in cells expressing constitutively active mutant IKK. This
result suggests that BDV directly interferes with the IKK/NF-kB pathway. To elucidate the mechanism for
the inhibition ofNF-kB activation by BDV infection, we evaluated the cross-talk betweenBDV infection and
the NF-kB pathway. Using Multiple EM for Motif Elicitation analysis, we found that the nucleoproteins of
BDV (BDV-N) and NF-kB1 share a common ankyrin-like motif. When THP1-CD14 cells were pre-treated
with the identified peptide, NF-kB activation by Toll-like receptor ligands was suppressed. The 20S
proteasome assay showed that BDV-N and BDV-N-derived peptide inhibited the processing of NF-kB1
p105 into p50. Furthermore, immunoprecipitation assays showed that BDV-N interacted with NF-kB1 but
not with NF-kB2, which shares no common motif with BDV-N. These results suggest BDV-N inhibits
NF-kB1 processing by the 20S proteasome through its ankyrin-like peptide sequence, resulting in the
suppression of IKK/NF-kB pathway activation. This inhibitory effect of BDV on the induction of the host
innate immunity might provide benefits against persistent BDV infection.
B
orna disease virus belongs to the orderMononegavirales and possesses a non-segmented, negative-stranded
RNA genome. The characteristic properties of this virus include its broad host range in vertebrates1–3 and its
ability to establish persistent infection in the cell nucleus4–6. The BDV genome encodes 6 genes in the
following 39 to 59 order: nucleoprotein (N), phosphoprotein (P), X, matrix protein (M), glycoprotein (G), and
polymerase protein (L)7–9. TheMprotein undercoats the viral envelope10,11, and theG proteinmediates viral entry
into host cells12–14. The N, P, and L proteins form the polymerase complex and perform roles in the transcription
and replication of the viral genome15–17.
Most likely due to the 39 to 59 transcription initiation gradient8, the N protein is the most abundant viral
proteins in acutely infected cells18 and animals19; it is also the dominant target of the humoral20 and CD81-T-cell-
mediated immune reactions21. In most infected cells, the N protein is concentrated in viral replication factories in
the nucleus22; however, it is capable of nucleocytoplasmic shuttling due to a nuclear export signal as well as a
nuclear localization signal23. These properties make N a strong candidate for a viral gene that influences host cell
functions, including innate immunity.
When a cell is infected with a virus, pattern recognition receptors (PRRs) rapidly sense non-self nucleic acids
and proteins, leading to the activation of the antiviral innate immune response24. One key downstream com-
ponent of this response, type I interferon, has been shown to inhibit BDV infection in a number of experimental
systems25,26. Given the wide range of cells in which BDV effectively establishes persistent infection, it is unsur-
prising that it has evolvedmany strategies to avoid triggering PRRs as well as to interrupt their signaling cascades.
BDVmodifies the termini of its RNA genome in a way that avoids recognition by the cytoplasmic innate receptor
RIG-I27,28. In addition, BDV can inhibit MAVS, a molecule important for activating transcription factors,
including IRF3 and 7, after PRR engagement29. Finally, BDV inhibits TBK-1, a kinase needed to phosphorylate
IRF3 and 7, which allows them to enter the nucleus to transcribe interferon and other innate immune effectors30.
Thus, BDV avoids or counteracts the innate immune response at multiple levels. Innate immune pathways are
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oughly antagonize the host response. For example, BDV is inhibited
by the constitutive activation of NF-kB31, but no BDV proteins that
interact with this molecule have been identified.
NF-kB is a transcription factor involved in immune induction,
embryonic development, and cell proliferation in response to various
extracellular stimuli32,33. The NF-kB family consists of five genes,
NF-kB1, NF-kB2, RelA, RelB, and c-Rel, which form homo- or hetero-
dimers in the cytoplasm34,35. When the NF-kB signaling pathway is
activated, IkB, which is an inhibitory factor of NF-kB, is phosphory-
lated by IkB kinase (IKK) and degraded by the 20S proteasome36. This
process frees NF-kB to translocate into the nucleus, where it behaves
as a transcription factor32,33. When cells expressing constitutively active
IKK are stimulated with tetradecanoyl phorbol acetate, a potent NF-
kB signaling pathway stimulus, NF-kB activation is lower in BDV-
infected cells than in mock cells. This difference suggests that BDV
infection suppresses the IKK/NF-kB signaling pathway downstream of
IKK31.
To better understand how BDV evades innate immunity and
establishes persistent infection, we first confirmed that BDV sup-
presses NF-kB activation, then aimed to determine the mechanism
by which it does so. It has previously been reported that certain cell-
penetrating peptides with sequence motifs in common with specific
NF-kB family genes can competitively inhibit the NF-kB signaling
pathway37–39. Furthermore, a viral peptide derived from the vaccinia
virus A46 protein (VIPER) inhibits the Toll-like receptor 4 (TLR4)
signaling pathway, which also mediates signal transduction using NF-
kB by binding to the BB loop of Toll/interleukin-1 receptor (TIR)
domains of the receptor and adaptor, thus disrupting the receptor-
adaptor interaction40,41. We thus searched the BDV proteins for motifs
shared with the NF-kB family proteins, aiming to identify NF-kB
inhibitory peptide sequences to elucidate the mechanism by which
BDV suppresses NF-kB activation.
Here, we show that BDV-N shares a common ankyrin-like motif
with NF-kB1. In cells, this BDV-N-derived peptide inhibits the NF-
kB signaling pathway. The inhibitory peptide derived from BDV-N
demonstrates another mechanism used by BDV to overcome innate
immunity and establish persistent infection.
Results
BDV infection inhibits NF-kB activation. To first assess the repro-
ducibility of the previous data that BDV suppresses the processing and
activation of NF-kB during infection31, we employed THP1-CD14
cells42. These cells express secreted alkaline phosphatase (SEAP) under
the control of a promoter that is activated by NF-kB. THP1-CD14
cells were infected with rBDV P/M-GFP43, and the resulting SEAP
activity was measured at from 12 h to 2 weeks post-infection. The
SEAP activity in the culture supernatant was not significantly elevated
above the level frommock-infected cells at any point over the 2 weeks
(Figure 1A), suggesting a lack of detectable NF-kB activation induced
by BDV infection in THP1-CD14 cells. In contrast, the addition of the
positive control, the TLR1/2 agonist Pam3CSK4, at a 100 ng/ml con-
centration for 24 hours led to readily detectable SEAP production.
These data could indicate that BDV avoids recognition by PRRs
that signal through NF-kB or, alternatively, that BDV may be reco-
gnized by such PRRs but their signaling is interrupted prior to the
activation of NF-kB. To distinguish between these alternatives, we
attempted to activate NF-kB in persistently BDV-infected cells using
Pam3CSK4. BDV-infected cells secreted less SEAP than mock cells
when activated with Pam3CSK4 (Figure 1B), suggesting that BDV-
infected cells actively suppress NF-kB signaling. To assess whether
Figure 1 | BDV infection suppresses NF-kB activation. (A) THP1-CD14 cells were infected with cell-free rBDV P/M-GFP at a multiplicity of infection
of 0.1, and the resulting supernatants were collected. The SEAP activity was determined at the indicated time points (N 5 3). (B) THP1-CD14 cells
infected with rBDV P/M-GFP were stimulated with 100 ng/ml of TLR1/2 ligand (Pam3CSK4). At 48 h post-stimulation, GFP-positive cells were
measured using an image-based cytometer. Error bars represent standard deviation of the mean (N5 3). **: P5 0.00474 (one-tailed t-test) (C) THP1-
CD14 cells infected with rBDV P/M-GFP were stimulated with 100 ng/ml of TLR1/2 ligand (Pam3CSK4). The SEAP activities of the supernatants were
determined at 24 h post-stimulation. Error bars represent the standard deviation of the mean (N 5 3). **: P 5 0.00761 (one-tailed t-test)
www.nature.com/scientificreports
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NF-kB activation has a deleterious effect on viral replication, we
activated NF-kB using Pam3CSK4 in cultures of THP1-CD14 cells
that had been exposed to BDV 7 days earlier. Forty-eight hours after
stimulation, we measured the extent of infection by determining
the percentage of GFP-expressing cells. NF-kB activation with
Pam3CSK4 resulted in significantly fewer BDV-infected cells in
the culture (Figure 1C). These data are consistent with a previous
report31 and indicate that BDV infection inhibits NF-kB activation,
which could otherwise impair BDV replication.
Inhibition of NF-kB activation by a peptide derived fromBDV-N.
Based on previous reports that peptides possessing common sequence
motifs with specific NF-kB family genes competitively inhibit NF-kB
signaling37–39 and that VIPER derived from vaccinia virus A46 protein
inhibits TLR4 signaling40,41, we screened for common motifs between
BDV genes and the human NF-kB family to identify possible mecha-
nisms underlying the observed inhibition of NF-kB activation in
BDV-infected cells. For this purpose, we used Multiple EM for Motif
Elicitation (MEME) analysis, a tool for the discovery of common
motifs across amino acids sequences that uses the MM algorithm44,45.
We detected several shared motifs (Table 1). We focused on a motif
shared between BDV-N and NF-kB1 because both the length of the
motif sequence (16 amino acids) and the localization of the motif
(ankyrin repeat domain of NF-kB132,33; exposed domain of BDV-N
tetramer and monomer46) suggested that it could have a biologically
relevant effect (Figure 2A and B).
To assess the inhibitory effect of the identified motif in BDV-N on
NF-kB activation, THP1-CD14 cells were incubated with 100 mg/ml
of the viral peptide fused with a cell-penetrating peptide (nine argi-
nine residues) at the C-terminus for 4 h. We then stimulated the cells
with five different TLR ligands known to activate NF-kB, predicting
that a direct interaction of the BDV-N peptide with NF-kB would
block SEAP production regardless of the upstream pathway involved.
Indeed, 24 h after stimulation with TLR ligands, NF-kB activation by
all ligands was significantly suppressed in cells pre-treated with virus
peptides derived from BDV-N (P5 0.00168 for TLR1/2; P5 0.01198
for TLR4; P 5 0.00090 for TLR2/6; P 5 0.00862 for TLR2; P 5
0.01337 for TLR7/8), as well as with the positive control VIPER
(P 5 0.00084 for TLR1/2; P 5 0.00823 for TLR4; P 5 0.00131 for
TLR2/6; P5 0.00203 for TLR2; P5 0.00646 for TLR7/8) (Figure 2C).
In contrast, NF-kB signaling was highly activated by all TLR agonists
in cells pre-treated with the control peptide CP7. These data suggest
that the identified viral peptide inhibits NF-kB activation. We there-
fore refer to this peptide as the Inhibitory Peptide derived from BDV-
N (IPBN).
BDV-N and the peptide derived from BDV-N reduce NF-kB1
processing by the 20S proteasome. The ankyrin repeat domain of
NF-kB1 represses its transcription activity. Upon NF-kB pathway
activation, NF-kB1 is phosphorylated, which promotes the process-
ing of the ankyrin repeat-containing C-terminal region by the 20S
proteasome and produces a shift in the molecular weight from 105
to 5036. We hypothesized that IPBN, and perhaps also intact BDV-N,
could inhibit NF-kB signaling by preventing this processing. To
determine whether IPBN affects the processing of NF-kB1 p105 into
p50, we performed an in vitro 20S proteasome assay using IPBN and
affinity-purified recombinant BDV-N and NF-kB1 proteins, as
previously reported36. As shown in Figure 3, when NF-kB1 was incu-
bated with the control peptide and then with the 20S proteasome,
p105 was markedly reduced, confirming NF-kB1 processing by the
20S proteasome. This processing could be effectively blocked using
a protease inhibitor cocktail. Recombinant BDV-N and IPBN sup-
pressed the processing of p105 as efficiently as the protease inhibitor
(P 5 0.03401 for BDV-N; P 5 0.03904 for IPBN; P 5 0.04556 for
protease inhibitor) (Figure 3A and B). These data suggest that BDV-
N and IPBN inhibit NF-kB activation by preventing NF-kB1 pro-
cessing by the 20S proteasome, allowing unprocessed NF-kB1 to act
as IkB37,38, the inhibitory factor of NF-kB.
The IPBN sequence is dispensable for the interaction of BDV-N
with NF-kB1.We focused our investigation on the BDV-N gene, as
it contains a peptide with similarity to the ankyrin repeat domain of
NF-kB. This peptide alone is capable of inhibiting NF-kB signal-
ing; however, intact BDV-N protein also inhibits the processing of
NF-kB1. Therefore, we determined whether intact BDV-N interacts
with NF-kB1 using an immunoprecipitation assay. Lysates from
cells expressing HA-tagged BDV-N and FLAG-tagged NF-kB1 or
FLAG-tagged NF-kB2 were mixed for 30 min at 4uC, and the
mixed cell lysates were immunoprecipitated with an anti-FLAG
antibody (SIGMA). As shown in Figure 4A, BDV-N was co-
immunoprecipitated with NF-kB1, but not with NF-kB2, which
shares no common motif with BDV-N. This result indicates that
BDV-N interacts specifically with NF-kB1. Interestingly, we found
that alanine substitution or deletion of the IPBN amino acid sequence
in BDV-N had no effect on co-immunoprecipitation with NF-kB1
(Figure 4B). Note that the increased binding property of L8A mutant
to NF-kB1might be resulted from its loose tetramer formation by the
alanine replacement. In fact, the L8A mutant has four amino acid
changes in the residues involved in the oligomerization of BDV-N,
while F8A contains only one change46. Thus, the identified motif
sequence is dispensable for the interaction of BDV-N with NF-kB1,
suggesting that BDV-N interacts with NF-kB1 via additional domains
not apparent at the level of motif similarity.
Discussion
The ankyrin repeat domain of NF-kB1 binds to its Rel homology
region, which leads to the repression of transcription factor activity
(Figure 2A). The phosphorylation of NF-kB1 (p105) by signal trans-
duction pathways induces the processing of its ankyrin repeat
domain by the 20S and 26S proteasomes, and the mature p50 form
gains transcription factor activity36,47. This study revealed that BDV
has an ankyrin-like motif in common with NF-kB1 in its N gene.
This peptide and intact BDV-N inhibit the processing of NF-kB1
from p105 to p50 by the 20S proteasome, suppressing NF-kB activa-
tion. At present, it is unclear exactly how BDV-N suppresses NF-kB1
processing by the 20S proteasome. However, we observed a direct
Table 1 | Extracted motifs
NF-kB Family BDV gene Motif sequence
NF-kB1 N BDV-N 187MFNPHEAIDWINGQPW202
NF-kB1 779MATSWQVFDILNGKPY794
NF-kB2 P BDV-P 145MKTMMETM162
NF-kB2 143KKNMMGTM160
RelA Not extracted
RelB N BDV-N 186QMFNPH191
RelB 556NMFPNH561
c-Rel G BDV-G 115DPFECNWFYCC125
c-Rel 560DAFEGSDFSCA571
www.nature.com/scientificreports
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interaction between BDV-N and NF-kB1. Furthermore, BDV-N
itself was not degraded by the 20S proteasome, suggesting that it
does not act as a decoy for NF-kB1 processing. The IPBN sequence
was not necessarily required for the interaction between BDV-N and
NF-kB1 (Figure 4B), indicating that at least one other domain within
N is necessary to mediate this interaction. Together, our data suggest
that the close proximity of BDV-N to NF-kB1 might be important
for the efficient inhibitory effects of BDV-N on NF-kB activation.
Our working hypothesis is that docking BDV-N onto NF-kB1might
mimic a longer ankyrin repeat domain, which has been reported to
exert a suppressive effect onNF-kB1 processing47. Structural analysis
shows that the ankyrin-like motif is exposed in the BDV-N tetramer
andmonomer46, consistent with this hypothesis (Figure 2B). However,
our report has several limitations. At first, we couldn’t detect the
mature p50 from in the 20S proteasome assay, because of the failure
to purify the recombinant NF-kB1 protein tagged at N-terminus, in
addition to the low reactivity of the anti-p50 antibodies. We were also
unable to test whether BDV-N interacts with NF-kB in infected cells
and to rescue recombinant BDV, which has no IPBN. Furthermore,
because the interaction of BDV-N with NF-kB1 is not strictly depend-
ent on the identified peptide, we are still exploring strategies to disrupt
this interaction while maintaining other critical virological functions
of N, which would allow us to definitively assess the relevance of this
interaction to BDV infection and persistence. We are now trying to
rescue serial mutants of BDV via alanine substitution in IPBN. Further
investigation is needed to elucidate the detailed mechanism of the
inhibitory effect of BDV-N and IPBN on NF-kB1.
We successfully identified the shared motif between BDV-N and
NF-kB1 using MEME analysis, which is a web server for discovering
common motif(s) in DNA or protein sequences through the MM
algorithm, an extension of the expectation maximization tech-
nique44,45. The identified motif was found to be well-conserved in
both the BDV and avian bornavirus nucleoproteins. In 202 of the
sequences available in GenBank at the time of submission, only two
conservative changes (M187V and G199A) were present at higher
than 15%. Indeed, the peptide generated from the identified motif
efficiently suppressed NF-kB activation, indicating that MEME ana-
lysis is a useful tool in the search for antagonized motifs of viral
protein to host genes. In addition to IPBN, we also found that the
V protein of theMeasles virus shares amotif with the TIR domains of
the TIR-domain-containing adapter-inducing interferon-b (TRIF)-
related adaptor molecule (TRAM) andmyeloid differentiation prim-
ary-response gene 88 (MyD88)-adaptor-like (MAL), which are the
adaptor proteins in the TLR signaling pathway48. The identified virus
peptide (DRWCNPMC), which fused with the cell-penetrating pep-
tide at the C-terminus, showed inhibitory effects on some of the TLR
signaling pathways (Figure S1; P5 0.00105 for TLR1/2; P5 0.10236
for TLR4; P 5 0.00475 for TLR2/6; P 5 0.00111 for TLR2; P 5
0.00596 for TLR7/8). These data also strongly support the usefulness
of this strategy.
Another interesting finding of this study is that the VIPER pep-
tide that we chose as a positive control inhibited NF-kB signaling
through all TLR agonists examined, as it has previously been
reported to be specific for the TLR4 pathway40,41. However, we
Figure 2 | Inhibitory effect of the virus peptide on NF-kB activation. (A) Schematic diagram of NF-kB1 and BDV-N. (B) The crystallographic structure
of the BDV-N tetramer and monomer (Protein Databank # 1N93). Yellow lines indicate the IPBN. (C) Inhibitory effect of the viral peptide on
NF-kB activation. THP1-CD14 cells were pre-treated with 100 mg/ml of the viral peptide derived from BDV-N, a negative control peptide (CP7), or the
positive control peptide (VIPER) and stimulated with five TLR ligands. At 24 h post-stimulation, the SEAP activities in the supernatants were measured.
Error bars represent the standard deviation of the mean (N 5 3).
www.nature.com/scientificreports
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Figure 3 | The 20S proteasome assay. (A)NF-kB1 protein and BDV-Nprotein, the virus peptide derived fromBDV-Nor 1X complete protease inhibitor
cocktail, were incubated with 20S proteasome at 37uC for 1 h. To detect the p105 form of NF-kB1, SDS-PAGE and western blotting with anti-FLAG
M2 monoclonal antibody were performed. BDV-N was detected using an anti-HA monoclonal antibody. Full-length blots are presented in
Supplementary Figure 2. (B) The intensities of the p105 bands were quantified by ImageJ. The relative amount of the output p105 compared with the
input p105 was calculated. The error bars represent the standard deviation of the mean (N 5 3).
Figure 4 | Interaction of BDV-N with NF-kB1. (A) Lysates from cells expressing HA-tagged BDV-N were mixed with lysates from cells transfected
with FLAG-tagged NF-kB1 or FLAG-tagged NF-kB2 for 30 min at 4uC. Mixed cell lysates were then immunoprecipitated with an anti-FLAG M2
monoclonal antibody using Protein G Dynabeads. SDS-PAGE and western blotting with an anti-HA monoclonal antibody and anti-FLAG M2
monoclonal antibody were performed. Full-length blots are presented in Supplementary Figure 3. (B) Lysates from cells expressing HA-tagged BDV-N
or HA-tagged IPBN-alanine substitution in the first 8 (F8A) or last 8 (L8A) amino acids or -deletion mutants (Dmotif) of BDV-N were mixed with
lysates from cells and transfected with the FLAG-tagged NF-kB1 for 30 min at 4uC. The mixed cell lysates were then subjected to an IP assay with anti-
FLAG M2 monoclonal antibody using Protein G Dynabeads. Full-length blots are presented in Supplementary Figure 4.
www.nature.com/scientificreports
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believe that our results are valid and suggest a previously unrecog-
nized breadth of VIPER inhibition. As shown in Figure 2, a control
peptide did not inhibit signaling by any of the agonists tested. The
identified peptide from the V protein of the Measles virus did not
inhibit NF-kB signaling by the TLR4 agonist and had approximately
half the inhibitory effect of either IPBN or VIPER on the other
pathways (Figure S1). Together with the control peptide data, this
result argues against a systemic bias toward pan-inhibition in our
experimental system.
BDV antagonizes host innate immune functions in many ways:
the genomic RNA of BDV escapes RIG-I recognition through the
processing of the 59 termini27,49; BDV-P counteracts Traf family
member associated NF-kB activator-binding kinase 1 (TBK-1)-
dependent IFN-b expression by acting as a competitive inhibitor of
TBK-130; and BDV-X inhibits mitochondrial antiviral signaling pro-
tein-induced apoptosis29. By showing for the first time that BDV
interacts with and inhibits NF-kB, a transcription factor used by
many innate immune pathways to transduce signals into the nucleus,
this study provides a key insight into how BDV might establish its
characteristic persistent infection in the cell nucleus.
In summary, we have identified a viral peptide that shares motifs
with and inhibits NF-kB, validating the use of theMEME tool for this
purpose. This peptide and other peptides identified in this way could
prove useful as pharmacological agents. IPBN inhibits NF-kB, which
is being explored as a therapy for many diseases, such as cancer,
asthma, and muscular dystrophy32,50. Furthermore, this result pro-
vides a starting point for dissecting virus/host protein interactions.
Future studies of BDV-N/NF-kB interaction are warranted to better
understand the strategies used by bornaviruses, which have been
infecting vertebrate hosts for millions of years51, to counter innate
immunity.
Methods
Cells, virus, and peptides. THP1-CD14 cells (InvivoGen, San Diego, CA, USA) were
maintained in Roswell Park Memorial Institute 1640 medium (SIGMA-ALDRICH
Japan, Tokyo, Japan) with 10% fetal calf serum (FCS), 1X Penicillin-Streptomycin
Solution (Wako, Osaka, Japan), 200 mg/ml of ZeocinTM (Life Technologies Japan,
Tokyo, Japan), 250 mg/ml of G418 (InvivoGen), and 100 mg/ml of Normocin
(InvivoGen). The 293T cells and BDV-infected Vero cells were grown in Dulbecco’s
modified Eagle’s minimal essential medium (Life Technologies Japan) with 10% FCS
and 1X Penicillin-Streptomycin Solution.
The virus used in this study was recombinant BDV, which expresses GFP inserted
between the P and M genes of BDV strain He/80, named rBDV P/M-GFP43,52. To
prepare cell-free rBDV P/M-GFP, Vero cells persistently infected with rBDV P/M-
GFPwere sonicated (BioRuptor UCD-300) and centrifuged at 12003 g for 25 min at
4uC. The supernatant was collected and used as cell-free rBDV P/M-GFP.
The virus-derived peptide (MFNPHEAIDWINGQPW), control peptide
(RNTISGNIYSA), and VIPER (KYSFKLILAEY) with cell-penetrating peptide (nine
arginine residues) at the C-terminus were custom synthesized (Life Technologies
Japan).
MEME analysis. Amino acid sequences of all BDV genes were submitted to the
MEME web server (http://meme.nbcr.net/meme/cgi-bin/meme.cgi) along with one
gene from each of the five humanNF-kB families. Themotif search criteria were set as
follows: the width of the motif ranged from 6 to 50 AA, with a maximum of 3 motifs
per gene and a maximum of 2 sites per motif.
NF-kB activation assay.THP1-CD14 cells express TLRs and CD14 at high levels and
express the SEAP gene in a NF-kB-dependent manner. To assess the SEAP
production, the culture supernatant of THP1-CD14 cells was incubated with
QUANTI-BlueTM (InvivoGen) for 1 h at 37uC, after which the optical density (OD) at
650 nm was measured using a Microplate reader SH-9000 (CORONA ELECTRIC
Co., Ltd). To assess the NF-kB activation by BDV infection, THP1-CD14 cells were
infected with cell-free rBDV P/M-GFP at a multiplicity of infection of 0.1, and the
supernatant was harvested and SEAP measured at 12 h, 1 d, 2 d, 3 d, and 2 weeks
post-infection. To evaluate the effect of NF-kB activation on BDV infection, a culture
of THP1-CD14 cells approximately 30% infected with rBDV P/M-GFP was
stimulated with 100 ng/ml of the TLR1/2 ligand. GFP-positive cells were measured
using a TaliH Image Cytometer (Life Technologies Japan) at 48 h post-stimulation,
and the SEAP activity was assessed at 24 h post-stimulation.
To evaluate the inhibitory effects of the virus peptide on NF-kB activation, 23 105
THP1-CD14 cells were incubated with 100 mg/ml of each peptide for 4 h at 37uC,
then subjected to stimulationwith 100 ng/ml of Pam3CSK4, 10 ng/ml of TLR4 ligand
(LPS), 10 ng/ml of TLR 2/6 ligand (FSL-1), 107 cells/ml of TLR2 ligand (heat killed L.
Monocytogenes), and 5 mg/ml of TLR 7/8 ligand (CL075) (all from InvivoGen),
respectively. At 24 h after stimulation, the SEAP activity of the supernatant was
determined as described above. The results shown represent the means of three
independent experiments. The P values were calculated using a one-tailed t-test.
The 20S proteasome assay. We performed the 20S proteasome assay as previously
described36. Briefly, BDV-N andNF-kB1 proteins were purified with antibodies using
Dynabeads Protein G (Life Technologies Japan). The NF-kB1 protein and BDV-N
protein, IPBN, or 1 X complete protease inhibitor cocktail (Roche Diagnostic K.K.,
Tokyo, Japan) were incubated with the 20S proteasome (Boston Biochem,
Cambridge, MA, USA) at a molecular ratio of 2552551 in a buffer solution (20 mM
Tris pH 7.0, 250 mM NaCl, 10 mM MgCl2, and 1 mM DTT) at 37uC for 1 h. The
resultant proteins were subjected to SDS-PAGE and western blotting with an anti-
FLAGM2 monoclonal antibody (SIGMA-ALDRICH Japan) to detect the p105 form
of NF-kB1. The p50 form was not detected because of the cleavage of the C-terminal
FLAG during 20S processing. BDV-N was detected using an anti-HA monoclonal
antibody.
Immunoprecipitation (IP) assay. For the IP assay, 293T cells were transfected with
pcDNA3 encoding BDV-N, alanine substitution mutants in the first 8 (F8A) or last 8
(L8A) amino acids of IPBN, or IPBN deletion mutants of BDV-N tagged with HA at
N-terminus, pCMV6 expressing NF-kB1 fused with FLAG-tag at C-terminus
(OriGene Technologies, Inc., Rockville, MD, USA), and pCMV6 expressing NF-kB2
fused with FLAG-tag at C-terminus (OriGene Technologies, Inc.), and the cells were
then lysed in a buffer containing 20 mMTris-HCl pH 7.4, 150 mMNaCl, 1%Triton-
X, 1 mM EDTA, and 1 X complete protease inhibitor cocktail. Cell lysate expressing
HA-tagged BDV-N or BDV-N mutants was mixed with cell lysate transfected with
FLAG-tagged NF-kB1 or FLAG-taggedNF-kB2 for 30 min at 4uC, and themixed cell
lysates were immunoprecipitated with anti-FLAG M2 monoclonal antibody using
Protein G Dynabeads, according to the manufacturer’s instructions. The mixed cell
lysates and IP products were subjected to SDS-PAGE and western blotting using an
anti-HA monoclonal antibody (Abcam, Cambridge, UK) and an anti-FLAG M2
monoclonal antibody.
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